JCyte

12/01/2025

jCyte is excited to share that Nature Magazine's Biopharma Dealmakers has published a new article spotlighting the promise of jCell (famzeretcel), our neuroprotective, allogeneic, and gene-agnostic retinal progenitor cell therapy for retinitis pigmentosa (RP) and other back of the eye indications.

Read the article: https://lnkd.in/g3r9PVtF

The piece highlights why jCell is uniquely positioned to serve the ~1.5 million people living with RP, most of whom have no treatment options. jCell is delivered via a simple intravitreal injection and works by releasing neurotrophic factors that support photoreceptor health and function.

Clinical findings have shown meaningful vision improvements that can appear within weeks and last a year or more from a single dose, an encouraging signal as we advance our ongoing Phase 2 trial, JC02-88. You can learn more about the trial below

JC02-88 Trial Information: https://www.jcyte.com/JC02-88-study/

We remain committed to moving this therapy forward with urgency, rigor, and an unwavering focus on patients.

hashtag hashtag

08/25/2025

We’re pleased to announce that results from jCyte’s Phase I/IIa safety study of retinal progenitor cells (jCell) in retinitis pigmentosa have been published in Frontiers in Cellular Neuroscience.

This publication marks another important milestone in advancing potential treatments for patients living with RP.

Read the full press release at the link below:

https://www.businesswire.com/news/home/20250825635791/en/jCyte-Announces-Publication-of-Phase-IIIa-Safety-Study-of-Retinal-Progenitor-Cells-in-Retinitis-Pigmentosa-in-Frontiers-in-Cellular-Neuroscience?_gl=1*1abhek2*_gcl_au*MTEzNTU5OTEyMS4xNzQ5NTczNTQx*_ga*OTM1NTQ4ODA4LjE3NDk1NzM1NDE.*_ga_ZQWF70T3FK*czE3NTYxNDQwMjgkbzEyJGcxJHQxNzU2MTQ0OTc0JGo1NSRsMCRoMA.

08/18/2025

We’re excited to share some big news from jCyte!

The first patients have now been treated in our new JC02-88 clinical trial. This study is testing a higher dose of our investigational therapy, jCell (famzeretcel), for people living with retinitis pigmentosa (RP)—a rare, inherited eye disease that leads to vision loss and blindness.

This milestone brings us one step closer to our mission: developing a treatment that has the potential to restore vision for patients with RP, no matter their genetic subtype.

We’re deeply grateful to the patients, families, researchers, and partners who make this journey possible. Together, we’re moving closer to a future with more hope for the RP community.

👉 Read more about the trial here: https://www.businesswire.com/news/home/20250818947550/en/jCyte-Inc.-Announces-First-Patients-Treated-in-JC02-88-Trial-for-Retinitis-Pigmentosa

jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study evaluating the safety and efficacy of jCell (famzer...

04/22/2025

Exciting news from jCyte! We are now recruiting patients for our JC02-88 clinical trial (NCT06912633), focused on adult patients with any form of retinitis pigmentosa (RP) - regardless of genetic cause - who live in Southern California.

This marks a significant milestone in our mission to bring hope and potential treatment options to those living with RP, many of whom currently have limited or no available therapies.

👉 Learn more and see if you or someone you know may qualify on the JC02-88 Study page: https://www.jcyte.com/JC02-88-study/

10/11/2024

🌍 Check out the powerful new documentary Blink by National Geographic!

After three of their four children are diagnosed with retinitis pigmentosa (RP), a family embarks on an extraordinary journey around the world to create lasting visual memories for their children before they lose their sight.

At jCyte, we are dedicated to addressing the unmet needs of people with RP and other degenerative eye diseases. Blink highlights the urgent need for innovation in the treatment of RP, a condition for which there is currently no cure. We are working relentlessly to develop an allogeneic cell therapy that may restore vision and provide hope to those living with this life-changing disease.

Learn more about the film and where to watch it below, along with additional information about RP from National Geographic.

🎥 Link to the documentary: https://films.nationalgeographic.com/blink

📰 Learn more about RP: https://www.nationalgeographic.com/science/article/retinitis-pigmentosa-blink-movie

When three of their four children are diagnosed with retinitis pigmentosa, a rare and incurable disease that leads to severe visual impairment, the Pelletier family’s world changes forever. In the face of this life-altering news, Edith Lemay, Sébastien Pelletier and their children set out on a tr...